22 December 2005
Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study
Dawn A. Marcus, Joseph M. FurmanMed Sci Monit 2006; 12(1): PI1-7 :: ID: 443201
Abstract
Background: Serotonergic triptan medications effectively reverse pain andassociated symptoms of migraine. Vestibular symptoms, including dizziness and vertigo, occur in aboutone-third of migraineurs. The most frequent and consistent balance symptom in migraineurs is motion sickness,which is experienced by about half of migraineurs and may be related to serotonergic influences. Thisdouble-blind, placebo-controlled, crossover pilot study was designed to test the hypothesis that pre-treatmentwith the serotonin agonist rizatriptan would prevent motion sickness provocation in headache-free migraineurs.Material/Methods: Ten healthy adult migraineurs (5 migrainous vertigo and 5 migraine without associatedvestibular symptoms) with a history of motion sickness were tested in three sessions: a baseline vestibularbattery and two motion sickness provocation sessions two hours following randomly ordered blinded pre-treatmentwith either oral rizatriptan 10 mg or placebo. Motion sickness was assessed using two standardized questionnaires.Results: Motion sickness scores were lower following pre-treatment with rizatriptan compared with placeboin subjects with migrainous vertigo. Rizatriptan did not affect motion sickness in migraineurs withoutvertigo. Otolith-ocular reflex sensitivity was reduced following pretreatment with rizatriptan in bothgroups. Conclusions: This is the first study in humans testing a triptan serotonin agonist as a preventivetool for motion sickness. Rizatriptan prevented the development of motion sickness and severe motionsickness symptoms in patients with migrainous vertigo. These pilot data suggest a possible role for serotoninin the development of motion sickness symptoms in migraineurs with migrainous vertigo.
Keywords: Cross-Over Studies, Double-Blind Method, Migraine Disorders - drug therapy, Motion Sickness - physiopathology, Placebos, Serotonin Receptor Agonists - therapeutic use, Triazoles - therapeutic use, Tryptamines - therapeutic use
808 14
Editorial
01 December 2023 : Editorial
Editorial: Outbreaks of Post-Pandemic Childhood Pneumonia and the Re-Emergence of Endemic Respiratory InfectionsDOI: 10.12659/MSM.943312
Med Sci Monit 2023; 29:e943312
In Press
01 Dec 2023 : Clinical Research
Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective St...Med Sci Monit In Press; DOI:
30 Nov 2023 : Review article
Decoding the Neurological Sequelae of General Anesthesia: A ReviewMed Sci Monit In Press; DOI:
30 Nov 2023 : Clinical Research
Enhanced Pain Relief and Muscle Growth in Individuals with Low Back Instability: The Impact of Blood Flow R...Med Sci Monit In Press; DOI:
29 Nov 2023 : Clinical Research
Comparative Analysis of Intramedullary Nail versus Plate Fixation for Fibula Fracture in Supination Externa...Med Sci Monit In Press; DOI:
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292